SALT LAKE CITY, Utah, Oct. 25, 2016 – Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker analysis of blood samples from the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial (NCT01147250).
“We know that cardiovascular risk is higher in people with diabetes and that cardiovascular disease negatively affects treatment outcomes,” said Riccardo Perfetti, head of Global Diabetes Medical Team, Sanofi. “Sanofi is committed to further exploring cardiovascular disease in this patient population. The biomarker work with Myriad RBM will allow us to further develop a molecular understanding of the cardiovascular risks in people with type 2 diabetes. Biomarker profiling supports our goal of developing potentially innovative new treatments for patients.”
Under the agreement, Sanofi will provide approximately 5,300 serum samples from the ELIXA trial. Myriad RBM will use its CustomMAP® platform to measure biomarkers that can predict cardiovascular and microvascular (renal and retinal) risk in people with type 2 diabetes. Financial terms of the deal were not disclosed.
“Biomarker profiling can support the accelerated development of potentially innovative, targeted treatments for people with diabetes,” said Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine at Harvard Medical School, senior physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital. “As the chair of the ELIXA Steering Committee, I am pleased that Sanofi is supporting this work, which will provide new insights for better predicting cardiovascular risk in people with diabetes and hopefully improve the beneficial effects of therapies.”
Myriad RBM’s DiscoveryMAP® platform was used with Sanofi’s ORIGIN1 trial to successfully identify biomarkers associated with cardiovascular events or death in people with pre-diabetes or early type 2 diabetes. The performance of these biomarkers was confirmed using Myriad RBM’s CustomMAP platform and samples from Sanofi’s HOPE trial.1
“In prior studies, we demonstrated the power of DiscoveryMAP to identify panels of biomarkers that have important diagnostic and prognostic applications for people at a higher risk of a cardiovascular event. This new agreement with Sanofi will expand upon that experience,” said Ralph McDade, Ph.D., president of Myriad RBM. “Our ultimate goal is to provide accurate estimates of the risk of a future cardiovascular event in patients so that drug developers and physicians can tailor care and achieve better health outcomes.”
About Human DiscoveryMAP®
DiscoveryMAP is for those who seek a thorough understanding of a compound’s biological activity, efficacy and safety profile, as well as the disease or condition being addressed. The DiscoveryMAP service products help increase the odds of identifying novel protein biomarker patterns in drug development or diagnostic discovery projects. These data can support critical go/no-go decisions or identify candidate panels for potential companion diagnostics. Once a pattern is discovered, it can be seamlessly converted into a CustomMAP for high volume sample processing resulting in better, more efficient clinical trials. More info »
About Myriad RBM
Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. Myriad RBM’s biomarker discovery platform provides clinical researchers and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company’s proprietary Multi Analyte Profiling (MAP) technology offers preclinical and clinical researchers with broad, cost-effective analyses of multiple proteins from a single, small sample volume. MAP technology also supports Myriad RBM’s drive to develop companion diagnostics in areas of unmet medical need such as neuropsychiatry, nephrology and immunology. More information about Myriad RBM can be found at www.myriadrbm.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
For more information:
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.